JNJ-40346527

DRUG3 trials

Sponsors

Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Janssen Research & Development, LLC, University of Oxford

Conditions

Alzheimer DiseaseArthritis, RheumatoidHealthMild Cognitive Impairment

Phase 1

A Single and Multiple Dose Study to Explore the Safety Of JNJ-40346527 In Healthy Volunteers

CompletedNCT01054014

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Health

Start: 2010-01-31End: 2011-01-31Updated: 2013-09-04

MIcroglial Colony Stimulating Factor-1 Receptor (CSF1R) in Alzheimer's Disease

TerminatedNCT04121208

University of OxfordAlzheimer Disease, Mild Cognitive Impairment

Start: 2021-04-07End: 2022-02-18Updated: 2024-05-09

Phase 2

A Study of JNJ-40346527 in Patients With Active Rheumatoid Arthritis Despite Disease-modifying Antirheumatic Drug Therapy

CompletedNCT01597739

Janssen Research & Development, LLCArthritis, Rheumatoid

Start: 2012-07-31End: 2013-04-30Updated: 2014-04-08

Related Papers

Results from a Phase IIA Parallel Group Study of JNJ-40346527, an Oral CSF-1R Inhibitor, in Patients with Active Rheumatoid Arthritis despite Disease-modifying Antirheumatic Drug Therapy

The Journal of Rheumatology2015-08-0168 citations